A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Subjects With Gastroparesis.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Subjects With Gastroparesis.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Metoclopramide (Primary)
  • Indications Diabetic gastroparesis
  • Focus Therapeutic Use
  • Acronyms MINT
  • Sponsors Evoke Pharma
  • Most Recent Events

    • 25 Apr 2016 Primary endpoint has been met. (The Primary Efficacy Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score.), as reported by Evoke Pharma media release.
    • 24 Jun 2015 According to an Evoke Pharma media release, data from this trial have been published in the Clinical Gastroenterology and Hepatology journal published by the American Gastroenterological Association (AGA).
    • 18 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top